2016
The Treatment of Melanoma Brain Metastases
Kibbi N, Kluger H. The Treatment of Melanoma Brain Metastases. Current Oncology Reports 2016, 18: 73. PMID: 27822695, DOI: 10.1007/s11912-016-0555-4.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesBrain metastasesSystemic therapyClinical trialsAsymptomatic brain metastasesPrognosis of patientsUntreated brain metastasesPopulation of patientsOngoing clinical trialsCentral nervous systemMBM patientsCerebral edemaTreatment landscapeImproved survivalIntracranial metastasesMetastatic melanomaStereotactic radiosurgeryNew therapiesLocal modalitiesNervous systemPatientsDrug AdministrationRegistration trialsMetastasisEarly intervention
2014
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 2014, 14: 4. PMID: 24423208, PMCID: PMC3896780, DOI: 10.1186/1475-2867-14-4.Peer-Reviewed Original ResearchRenal cell carcinomaMicrovessel areaHighest microvessel areaSorafenib responseCell carcinomaMetastatic renal cell carcinomaCD 34 stainingSmall primary tumorsProgression-free survivalAnti-angiogenic therapyVEGF-R2 inhibitorsAdditional patientsPatient selectionPredictive biomarkersPrimary tumorSorafenib sensitivityTumor specimensDrug AdministrationVEGF-R3VEGF-R1Immunofluorescence-based methodTumor samplesVEGF-R2C-kitPatients
2012
Drug targets and predictive biomarkers in the management of metastatic melanoma
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics And Personalized Medicine 2012, Volume 5: 139-148. PMID: 23226069, PMCID: PMC3513235, DOI: 10.2147/pgpm.s25100.Peer-Reviewed Original ResearchMetastatic melanomaPredictive biomarkersApproval of ipilimumabChoice of treatmentImmune system characteristicsFederal Drug AdministrationClinical benefitTherapeutic optionsFatal skin cancerTreatment strategiesDrug combinationsMelanoma treatmentPromising drugAntitumor effectsDrug AdministrationSkin cancerIndividual tumorsMelanomaPersonalized therapyTherapyTreatmentDrug targetsBiomarkersIpilimumabTumors